Navigation Links
Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
Date:12/10/2007

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL), today reported phase 1 data from an ongoing phase 1 trial of XL019 in patients with myelofibrosis, a myeloproliferative disorder (MPD). XL019 is an investigational small molecule that selectively inhibits the tyrosine kinase JAK2, one of four JAK family members activated in response to cytokines and hematopoietic growth factors. JAK2 is inappropriately activated in the majority of MPD patients and is deregulated in a number of solid tumors, including certain subtypes of lymphoma. Dr. Srdan Verstovsek from the M. D. Anderson Cancer Center, Houston, TX today presented data from an ongoing phase 1 study in an oral presentation session (Abstract #553) at the American Society of Hematology 49th Annual Meeting and Exposition, which is taking place in Atlanta, December 8th-11th.

"We are very encouraged by the results from this ongoing trial that show rapid decrease in spleen size and relief of disease-related symptoms at low doses of XL019. XL019 is a highly selective inhibitor of JAK2 that may have the potential to provide important benefit for patients with myeloproliferative disorders and other diseases driven by JAK2," said Michael Morrissey, Ph.D., president of research and development at Exelixis. "We believe that JAK2 is a critical target in myeloproliferative disorders, and effective inhibition of JAK2 may directly translate into clinical benefit. The strong linkage of JAK2 to MPDs provides a potentially quick route to market, with potential for additional opportunities in larger commercial indications. We are planning to initiate pivotal trials of XL019 in myelofibrosis patients in 2008."

Trial Design

The phase 1 dose escalation study of XL019 is ongoing in subjects with primary myelofibrosis (MF) and post-polycythemia vera/essential thrombocythemia MF. To date nine patients have been enrolled. The primary objective of this study is to determine the safety and tol
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
9. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
10. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... SAN ANTONIO, Texas , Sept. 18, 2014  Casen ... vessels, skin and muscles to harden.  His case is one ... (GVM) in the world.  The only hospital in ... few in the world, offering treatment with the dual wave-length ... in San Antonio . Using a laser ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... companies. Competition for innovation, increasing clinical development costs, ... with the fast-changing environment are important factors driving ... and clinical trial costs continue to rise due ... Studies conducted by industry think tanks suggest ...
(Date:9/18/2014)... NORTHVALE, N.J. , Sept. 18, 2014 /PRNewswire/ ... Gianluca DeNovi , Ph.D. to its corporate ... DeNovi is an instructor at the Harvard Medical ... Bio-Medico of Rome.  He received his Masters degree ... and Control Systems from the University of Bologna. After ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Daily supplements of selenium ... the development of age-related cataracts among men, a new ... one or both could help prevent cataracts. To investigate ... and Harvard Medical School in Boston, and his colleagues ... and vitamin E. The trial was initially designed to ...
(Date:9/18/2014)... TayganPoint Consulting Group, a leading strategic ... co-founder John Cassimatis was named as one of ... recognizing the region’s top healthcare and life science ... the year. , The Innovation Awards celebrate companies ... to shape the medical industry in Greater Philadelphia ...
(Date:9/18/2014)... Stealth Health Revolution co-founders, Montel ... Frank Davis, founder of Food for Health International ... to announce the new recipe book, "The Simple ... meals using Activz whole-food powders." The Simple ... the Stealth Health Revolution mission to ...
(Date:9/18/2014)... companies can expect to pay higher employee contributions for ... human resource officers about the impact of the Patient ... or Obamacare) conducted by the Darla Moore School of ... May/June. , Patrick Wright, a professor in strategic human ... Chief HR Officers. The survey is distributed to more ...
(Date:9/18/2014)... develop tools that would allow them to clearly view ... neuron fires to the resulting behavior in a whole ... to develop a range of new tools to study ... tool that provides a new way of mapping neural ... between Viviana Gradinaru (BS ,05), assistant professor of biology ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 2Health News:Montel Williams and Frank Davis Announce New Whole-Food Nutrition Recipe Book, The Simple Scoop, at Natural Products Expo East In Baltimore 3Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 2Health News:Survey: Fortune 500 employees can expect to pay more for health insurance 3Health News:Sensing neuronal activity with light 2Health News:Sensing neuronal activity with light 3Health News:Sensing neuronal activity with light 4Health News:Sensing neuronal activity with light 5
... May 13th at Long Beach Veterans Administration Hospital, ... West Hills/Northridge,Veterans Administration will honor Dr. Richard Merkin, ... the health of American,war veterans. The VA, in ... a clinical research study aimed at,examining diabetic ulcers ...
... Colo., April 24 Heska Corporation,(Nasdaq: HSKA ) announces the following Webcast:, ... Earnings Conference Call on the Web, ... (click on the Q1 2008 Earnings Call link on ... Live over the Internet -- Simply log on to the web at the address ...
... Members, Elect New Member to Board, Reject ... Stockholder Proposals - ... -, MADISON, N.J., April 24 At today,s Annual,Meeting of Stockholders ... 12 current members of the Company,s Board of,Directors and elected nominee Michael ...
... David B. Snow,Jr., chairman & chief executive officer ... scheduled to address the Morgan Stanley Global Healthcare,Unplugged Conference ... The presentation at the Ritz-Carlton, Key Biscayne, will begin ... financial officer, is also,scheduled to attend., The presentation ...
... New Call Center, WASHINGTON, April 24 On ... contacting nearly 570,000,recent combat veterans to ensure they know ... reach out and touch every veteran of Operation Enduring,Freedom ... are here for them,",said Dr. James B. Peake, Secretary ...
... concepts through abstract cases more likely to retain knowledge, ... The use of "real-world" concrete examples doesn,t help students ... that challenges the widespread use of this approach in ... who learned a mathematical concept with concrete examples couldn,t ...
Cached Medicine News:Health News:Veterans Honor Dr. Richard Merkin During Research Week 2Health News:Webcast Alert: Heska Announces First Quarter 2008 Earnings Conference Call Webcast 2Health News:Wyeth Holds Annual Meeting of Stockholders 2Health News:Wyeth Holds Annual Meeting of Stockholders 3Health News:Wyeth Holds Annual Meeting of Stockholders 4Health News:Medco CEO to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2Health News:VA Calling All Recent Combat Vets 2Health News:'Real World' Examples Don't Make Math Any Easier 2
Cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, wedge-shaped inferior edge with, blunt tip, 0.6 mm dual sideports, 20 gauge....
Irrigating nucleus chopper, semi-sharp, wedge shaped inferior edge with a pointed tip, dual sideports, 20 gauge. For Phakonit cataract surgery....
Medicine Products: